— Deere & Company (NYSE: DE) reported its fourth-quarter 2019 adjusted earnings of $2.14 per share versus $2.13 per share expected.
— Total revenues increased by 5% to $9.9 billion. Sales in Equipment Operations rose by 4% to $8.7 billion versus $8.53 billion expected.

— The results reflected continued uncertainties in the agricultural sector. Many farmers remained cautious about making major investments in new equipment due to lingering trade tensions as well as difficult growing and harvesting conditions.
— Sales in Agriculture & Turf rose 3% to $5.8 billion due to price realization and higher shipment volumes, partially offset by the unfavorable effects of currency translation.
— Construction & Forestry sales grew by 8% to $2.95 billion helped by higher shipment volumes and price realization, partially offset by the unfavorable effects of currency translation.
— Financial Services posted a 66% dip in net income to $90 million, mainly due to impairments and higher losses on operating-lease residual values and unfavorable financing spreads.
— Looking ahead into fiscal 2020, net income attributable to Deere & Company is forecast to be in the range of $2.7 billion to $3.1 billion. The long-term outlook for its businesses remained healthy and points a promising future.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs